Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

Summary

This Phase 2, multi-center, open-label extension trial will provide CAP-1002 to participants who were randomized to the Usual Care treatment group of the HOPE-Duchenne study (NCT02485938) and completed 12 months of follow-up. The trial will assess the safety and efficacy of two intravenous administrations of CAP-1002, each separated by three months.

Timeline

Start

2018-06-21

Primary completion

2019-03-06

Completion

2019-03-06

Drugs

Indications